SG10201405311TA - Compounds and compositions as protein kinase inhibitors - Google Patents

Compounds and compositions as protein kinase inhibitors

Info

Publication number
SG10201405311TA
SG10201405311TA SG10201405311TA SG10201405311TA SG10201405311TA SG 10201405311T A SG10201405311T A SG 10201405311TA SG 10201405311T A SG10201405311T A SG 10201405311TA SG 10201405311T A SG10201405311T A SG 10201405311TA SG 10201405311T A SG10201405311T A SG 10201405311TA
Authority
SG
Singapore
Prior art keywords
compositions
compounds
protein kinase
kinase inhibitors
inhibitors
Prior art date
Application number
SG10201405311TA
Other languages
English (en)
Inventor
Shenlin Huang
Xianming Jin
Zuosheng Liu
Daniel Poon
John E Tellew
Yongqin Wan
Xing Wang
Yongping Xie
Original Assignee
Irm Llc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42782253&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201405311T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc, Novartis Ag filed Critical Irm Llc
Publication of SG10201405311TA publication Critical patent/SG10201405311TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
SG10201405311TA 2009-08-28 2010-08-27 Compounds and compositions as protein kinase inhibitors SG10201405311TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23807309P 2009-08-28 2009-08-28
US31303910P 2010-03-11 2010-03-11

Publications (1)

Publication Number Publication Date
SG10201405311TA true SG10201405311TA (en) 2014-09-26

Family

ID=42782253

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012009304A SG178351A1 (en) 2009-08-28 2010-08-27 Compounds and compositions as protein kinase inhibitors
SG10201405311TA SG10201405311TA (en) 2009-08-28 2010-08-27 Compounds and compositions as protein kinase inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012009304A SG178351A1 (en) 2009-08-28 2010-08-27 Compounds and compositions as protein kinase inhibitors

Country Status (50)

Country Link
US (12) US8501758B2 (ko)
EP (2) EP2470526B1 (ko)
JP (2) JP5475888B2 (ko)
KR (1) KR101413392B1 (ko)
CN (2) CN103896921B (ko)
AR (1) AR077975A1 (ko)
AU (1) AU2010286569C1 (ko)
BR (1) BR112012004453B1 (ko)
CA (1) CA2771775C (ko)
CL (1) CL2012000340A1 (ko)
CO (1) CO6612222A2 (ko)
CR (1) CR20120102A (ko)
CU (1) CU24110B1 (ko)
CY (3) CY1118452T1 (ko)
DK (2) DK2470526T3 (ko)
DO (1) DOP2012000051A (ko)
EA (2) EA201500175A1 (ko)
EC (2) ECSP12011700A (ko)
ES (2) ES2610825T3 (ko)
GE (1) GEP20146102B (ko)
GT (1) GT201200053A (ko)
HK (1) HK1167390A1 (ko)
HN (1) HN2012000441A (ko)
HR (2) HRP20140799T1 (ko)
HU (3) HUE032847T2 (ko)
IL (1) IL218084A (ko)
IN (1) IN2012DN02469A (ko)
JO (1) JO3002B1 (ko)
LT (3) LT2727918T (ko)
LU (1) LUC00101I2 (ko)
MA (1) MA33604B1 (ko)
ME (2) ME02684B (ko)
MX (1) MX2012002546A (ko)
MY (1) MY156259A (ko)
NI (1) NI201200029A (ko)
NL (1) NL300973I2 (ko)
NO (1) NO2019011I1 (ko)
NZ (1) NZ598924A (ko)
PE (1) PE20120861A1 (ko)
PL (2) PL2727918T3 (ko)
PT (2) PT2727918T (ko)
RS (2) RS55568B1 (ko)
SG (2) SG178351A1 (ko)
SI (2) SI2470526T1 (ko)
SM (2) SMT201400133B (ko)
TN (1) TN2012000081A1 (ko)
UA (1) UA112285C2 (ko)
UY (1) UY32860A (ko)
WO (1) WO2011025927A1 (ko)
ZA (1) ZA201202020B (ko)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
MX360932B (es) 2010-02-25 2018-11-21 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
US8907270B2 (en) 2010-06-30 2014-12-09 Schlumberger Technology Corporation Method and apparatus for gain regulation in a gamma detector
CN108542906A (zh) * 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
CN103945831A (zh) 2011-11-23 2014-07-23 诺华股份有限公司 医药制剂
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
TW201332988A (zh) * 2011-12-23 2013-08-16 Millennium Pharm Inc 雜芳基化合物及其用途
KR20140139510A (ko) 2012-03-28 2014-12-05 다나-파버 캔서 인스티튜트 인크. Raf 억제제에 대한 내성을 부여하는 c-raf 돌연변이체
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
JP6215324B2 (ja) 2012-07-18 2017-10-18 セントルイス ユニバーシティ インテグリンアンタゴニストとしてのβアミノ酸誘導体
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
LT2882440T (lt) * 2012-08-07 2019-04-25 Novartis Ag Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį
ES2743427T3 (es) 2012-08-17 2020-02-19 Hoffmann La Roche Politerapias para melanoma que comprenden administrar cobimetinib y vemurafinib
US20150232452A1 (en) * 2012-09-19 2015-08-20 Ruga Corporation Novel raf kinase inhibitors
CA2890663A1 (en) * 2012-11-08 2014-05-15 Novartis Ag Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
AU2014233805B2 (en) 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
SG11201509338QA (en) 2013-05-30 2015-12-30 Plexxikon Inc Compounds for kinase modulation, and indications therefor
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
MX2016008201A (es) * 2013-12-20 2017-04-27 Biomed Valley Discoveries Inc Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
CN105848682A (zh) * 2013-12-23 2016-08-10 诺华股份有限公司 药物组合
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
DE102015103158A1 (de) 2014-03-04 2015-09-10 Bergische Universität Wuppertal Verbindungen für die Behandlung des Melanoms
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP3143166A4 (en) 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)
EP3191478B1 (en) * 2014-09-12 2019-05-08 Novartis AG Compounds and compositions as raf kinase inhibitors
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
KR20170129802A (ko) 2015-03-10 2017-11-27 아두로 바이오테크, 인코포레이티드 ＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
RU2729518C2 (ru) 2015-12-30 2020-08-07 Сент-Луис Юниверсити Мета-азациклические производные аминобензойной кислоты в качестве антагонистов пан-интегрина
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
CR20190002A (es) 2016-06-03 2019-06-10 Zhu Alexander Cao Combinaciones farmacéuticas
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JP7076741B2 (ja) 2016-12-27 2022-05-30 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107540699A (zh) * 2017-10-16 2018-01-05 康化（上海）新药研发有限公司 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法
WO2019133810A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
WO2020011141A1 (zh) * 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CN113811303A (zh) 2019-05-16 2021-12-17 伊莱利利公司 用于治疗brafv600e结直肠癌的erk1/2抑制剂与braf抑制剂和egfr抑制剂的三药组合
US20230036867A1 (en) 2019-12-05 2023-02-02 INSERM (Institut National de la Santé et de la Recherche Médicale) N-(3-(5-(pyrimidin-4-yl)thiazol-4-yl)phenyl)sulfonamide compounds and their uses as braf inhibitors
WO2022036176A1 (en) 2020-08-13 2022-02-17 Albert Einstein College Of Medicine N-cyclyl-sulfonamides useful for inhibiting raf
EP4225307A1 (en) 2020-10-05 2023-08-16 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
KR20240008410A (ko) 2021-06-09 2024-01-18 에프. 호프만-라 로슈 아게 암 치료를 위한 병용요법
CN114181197B (zh) * 2022-02-16 2022-05-06 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104250A (en) * 1976-08-11 1978-08-01 Borg-Warner Corporation Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
DE3571974D1 (en) 1984-12-06 1989-09-07 Pfizer Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
AU7106996A (en) 1995-09-07 1997-03-27 Fuisz Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AU728701B2 (en) 1996-05-23 2001-01-18 Applied Research Systems Ars Holding N.V. Compounds that inhibit the binding of Raf-1 or 14-3-3 proteins to the beta chain of IL-2 receptor, and pharmaceutical compositions containing same
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EA003925B1 (ru) 1997-05-22 2003-10-30 Дж.Д.Сирл Энд Ко ЗАМЕЩЕННЫЕ ПИРАЗОЛЫ, КАК ИНГИБИТОРЫ p 38 КИНАЗЫ
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
WO2001047492A1 (en) 1999-12-23 2001-07-05 F H Faulding & Co Limited Improved pharmaceutical compositions for poorly soluble drugs
AU2001285349A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The University Of Arkansas Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CN100506224C (zh) 2001-10-25 2009-07-01 诺瓦提斯公司 包含选择性环加氧酶-2抑制剂的组合
AU2002356301A1 (en) 2001-12-21 2003-07-15 Cancer Research Technology Ltd. 3,4-diarylpyrazoles and their use in the therapy of cancer
PT2275102E (pt) 2002-03-13 2015-10-27 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
WO2005027972A2 (en) 2003-09-23 2005-03-31 Novartis Ag Combination of a vegf receptor inhibitor with a chemotherapeutic agent
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
US20090149469A1 (en) 2004-01-09 2009-06-11 Carlos Garcia-Echeverria Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl]-amine derivatives as igf-ir inhibitors
MY144044A (en) 2004-06-10 2011-07-29 Irm Llc Compounds and compositions as protein kinase inhibitors
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
AU2006227447A1 (en) 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-RAF kinase
US20070099856A1 (en) 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
US7608635B2 (en) 2005-08-12 2009-10-27 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
JP2009504796A (ja) 2005-08-22 2009-02-05 ノバルティス アクチエンゲゼルシャフト ｐＨ依存性薬剤化合物、ｐＨ調整剤および遅延剤を含む医薬組成物
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
EP2024353A2 (en) 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazole compounds
JP2009532497A (ja) 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
EP2013218A2 (en) * 2006-04-17 2009-01-14 Arqule, Inc. Raf inhibitors and their uses
SG174772A1 (en) 2006-09-11 2011-10-28 Curis Inc Multi-functional small molecules as anti-proliferative agents
DK2068880T3 (da) 2006-09-18 2012-07-23 Boehringer Ingelheim Int Fremgangsmåde til behandling af cancer, der huser EGFR-mutationer
WO2008042639A1 (en) 2006-10-02 2008-04-10 Irm Llc Compounds and compositions as protein kinase inhibitors
US20100087464A1 (en) * 2006-10-06 2010-04-08 Irm Llc Protein kinase inhibitors and methods for using thereof
AU2008216327A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of LBH589 with other therapeutic agents for treating cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
KR20100038119A (ko) * 2007-08-01 2010-04-12 화이자 인코포레이티드 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도
BRPI0818340A2 (pt) 2007-10-19 2015-04-22 Abbott Gmbh & Co Kg Produto de dispersão sólida de fármacos baseados em n-aril uréia
ES2637794T3 (es) * 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
CN102015686B (zh) * 2008-03-21 2014-07-02 诺华股份有限公司 杂环化合物及其用途
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
SI2324008T1 (sl) 2008-07-24 2012-08-31 Nerviano Medical Sciences Srl 3,4-diarilpirazoli kot protein-kinazni inhibitorji
US8088771B2 (en) 2008-07-28 2012-01-03 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene inhibitor compounds
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
HUE030800T2 (en) 2008-10-07 2017-05-29 Astrazeneca Uk Ltd Pharmaceutical Form No. 514
US20110293750A1 (en) * 2008-11-11 2011-12-01 Yale University Activated wnt-beta-catenin signaling in melanoma
JP5490137B2 (ja) * 2008-12-19 2014-05-14 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ プロテインキナーゼ阻害薬としての二環式ピラゾール
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) * 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
ES2570756T3 (es) * 2009-06-15 2016-05-20 Nerviano Medical Sciences Srl Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa
KR101256018B1 (ko) * 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
WO2011092088A1 (en) 2010-01-27 2011-08-04 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
JP6155187B2 (ja) 2010-03-30 2017-06-28 ヴァーセオン コーポレイション トロンビンの阻害剤としての多置換芳香族化合物
US9114137B2 (en) 2010-08-03 2015-08-25 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
DK2688572T3 (en) 2011-03-21 2017-06-12 Valcuria Ab PHARMACEUTICAL COMPOSITION WITH AN HDAC INHIBITOR AND A STEROID AND USE THEREOF
PE20140604A1 (es) 2011-06-14 2014-05-13 Novartis Ag Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
CN103945831A (zh) 2011-11-23 2014-07-23 诺华股份有限公司 医药制剂
CA2890663A1 (en) 2012-11-08 2014-05-15 Novartis Ag Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
US10576680B2 (en) 2015-11-19 2020-03-03 The Boeing Company Modular thermoforming system

Also Published As

Publication number Publication date
NI201200029A (es) 2012-05-29
JP5475888B2 (ja) 2014-04-16
US9593099B2 (en) 2017-03-14
PL2727918T3 (pl) 2017-06-30
NO2019011I1 (no) 2019-03-05
PL2470526T3 (pl) 2014-10-31
US9850230B2 (en) 2017-12-26
US20160120866A1 (en) 2016-05-05
EA201500175A1 (ru) 2015-05-29
CN102725283B (zh) 2014-02-26
JP6045519B2 (ja) 2016-12-14
HRP20170005T1 (hr) 2017-03-10
TN2012000081A1 (en) 2013-09-19
BR112012004453A8 (pt) 2021-06-08
US9850229B2 (en) 2017-12-26
PT2470526E (pt) 2014-09-01
JP2014098022A (ja) 2014-05-29
ECSP23004573A (es) 2023-04-28
US20130296318A1 (en) 2013-11-07
US20180297985A1 (en) 2018-10-18
LUC00101I1 (ko) 2019-02-13
ME01860B (me) 2014-12-20
SI2470526T1 (sl) 2014-09-30
CY1118452T1 (el) 2017-07-12
KR20120062839A (ko) 2012-06-14
SG178351A1 (en) 2012-03-29
JO3002B1 (ar) 2016-09-05
HN2012000441A (es) 2015-01-05
SMT201700036B (it) 2017-03-08
CU24110B1 (es) 2015-07-30
HUE032847T2 (hu) 2017-11-28
BR112012004453B1 (pt) 2022-04-26
EA201200373A1 (ru) 2012-09-28
MX2012002546A (es) 2012-04-11
DK2470526T3 (da) 2014-08-25
BR112012004453A2 (pt) 2021-03-09
US20160280686A1 (en) 2016-09-29
NL300973I1 (ko) 2019-03-27
DOP2012000051A (es) 2012-05-31
AU2010286569C1 (en) 2019-11-28
LTC2470526I2 (lt) 2020-04-27
MA33604B1 (fr) 2012-09-01
ZA201202020B (en) 2012-12-27
US10576080B2 (en) 2020-03-03
CY2019014I1 (el) 2019-11-27
GT201200053A (es) 2014-03-27
JP2013503186A (ja) 2013-01-31
US20230116233A1 (en) 2023-04-13
NL300973I2 (nl) 2022-05-05
CY2019013I1 (el) 2019-11-27
US20160263113A1 (en) 2016-09-15
AU2010286569B2 (en) 2013-10-10
US20160122324A1 (en) 2016-05-05
UY32860A (es) 2011-03-31
NZ598924A (en) 2013-07-26
CY2019013I2 (el) 2019-11-27
CN103896921A (zh) 2014-07-02
ES2610825T3 (es) 2017-05-03
USRE49556E1 (en) 2023-06-20
PT2727918T (pt) 2017-01-20
US10568884B2 (en) 2020-02-25
CO6612222A2 (es) 2013-02-01
US8501758B2 (en) 2013-08-06
LTPA2019006I1 (lt) 2019-03-25
CR20120102A (es) 2012-05-02
EP2470526A1 (en) 2012-07-04
EP2470526B1 (en) 2014-05-28
GEP20146102B (en) 2014-05-27
US20200323852A1 (en) 2020-10-15
US20110306625A1 (en) 2011-12-15
CN103896921B (zh) 2016-02-24
HUS1900013I1 (hu) 2019-04-29
LT2727918T (lt) 2017-01-25
US10005761B2 (en) 2018-06-26
DK2727918T3 (da) 2017-01-23
LTPA2019005I1 (lt) 2019-03-25
EA025222B1 (ru) 2016-12-30
SMT201400133B (it) 2014-11-10
HRP20140799T1 (hr) 2014-11-07
ECSP12011700A (es) 2012-03-30
RS53489B1 (en) 2015-02-27
WO2011025927A1 (en) 2011-03-03
CU20120034A7 (es) 2012-06-21
IL218084A0 (en) 2012-04-30
AU2010286569A1 (en) 2012-04-12
SI2727918T1 (sl) 2017-02-28
ES2492499T3 (es) 2014-09-09
UA112285C2 (uk) 2016-08-25
CA2771775C (en) 2015-01-20
RS55568B1 (sr) 2017-05-31
ME02684B (me) 2017-06-20
EP2727918A1 (en) 2014-05-07
EP2727918B1 (en) 2016-10-12
IN2012DN02469A (ko) 2015-08-21
CN102725283A (zh) 2012-10-10
HUS1900012I1 (hu) 2019-04-29
AR077975A1 (es) 2011-10-05
CL2012000340A1 (es) 2012-08-17
CY2019014I2 (el) 2019-11-27
CA2771775A1 (en) 2011-03-03
US9314464B2 (en) 2016-04-19
IL218084A (en) 2016-11-30
US20160280687A1 (en) 2016-09-29
PE20120861A1 (es) 2012-07-14
US20180297986A1 (en) 2018-10-18
US9593100B2 (en) 2017-03-14
HK1167390A1 (en) 2012-11-30
LUC00101I2 (ko) 2020-01-23
KR101413392B1 (ko) 2014-06-27
MY156259A (en) 2016-01-29

Similar Documents

Publication Publication Date Title
HUS1900012I1 (hu) Vegyületek és készítmények protein-kináz inhibitorokként
HUS1900014I1 (hu) Proteinkináz inhibitorok
PL2470528T3 (pl) Związki i kompozycje jako inhibitory kinazy białkowej
HRP20130698T1 (en) Novel phenylpyrazinones as kinase inhibitors
HRP20130787T1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
IL206416A0 (en) Benzofuropyrimidinones as protein kinase inhibitors
PT2200436E (pt) Pirimidinilaminas substituídas como inibidoras da proteína quinase
PL2193133T3 (pl) Imidazolotiadiazole do stosowania jako inhibitory kinazy białkowej
IL210073A0 (en) Protein kinase inhibitors
EP2387572A4 (en) PROTEIN KINASE C HEMMER AND ITS USE
IL210069A0 (en) Protein kinase inhibitors
HK1156306A1 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases hif--4-
EP2231152A4 (en) THIENOPYRANONES AS KINASE INHIBITORS
GB0807642D0 (en) IKK- serine-threonine protein kinase inhibitors